An Executive Order signed by President Trump aims to increase research, incentives, and treatment access for kidney disease patients and could 'fundamentally transform kidney therapeutics,' says president of the American Society of Nephrology....
Fresenius Medical Care integrates Frenova Renal Research into its global office in an aim to extend clinical research activities and reach more than 550 researchers.
AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.
The American Renal Associates has initiated an investigative site network to bring clinical research to patients while delivering care – and study management services to CROs and sponsors.
Evotec is collaborating with academic institutions to develop a device to test drug candidates in the kidney, which it says could improve and accelerate clinical trials.
Medpace stresses a continued investment in human resources as it anticipates growth and further opportunities from the small- and mid-sized biopharma market.
Evotec has joined a consortium through which it gains access to a sample biobank in order to perform drug discovery based on unique kidney disease patient cohorts.
Researchers have discovered a genetic defect that causes a serious
kidney disease, thus opening the door to new therapies that could
avoid the need for a transplant.
